J. Tillner

1.9k total citations
29 papers, 880 citations indexed

About

J. Tillner is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, J. Tillner has authored 29 papers receiving a total of 880 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Molecular Biology. Recurrent topics in J. Tillner's work include Diabetes Treatment and Management (9 papers), HER2/EGFR in Cancer Research (9 papers) and Lung Cancer Treatments and Mutations (8 papers). J. Tillner is often cited by papers focused on Diabetes Treatment and Management (9 papers), HER2/EGFR in Cancer Research (9 papers) and Lung Cancer Treatments and Mutations (8 papers). J. Tillner collaborates with scholars based in Germany, United States and Sweden. J. Tillner's co-authors include Federico Rojo, Dirk Weber, Lenore Teichert, U. Vanhoefer, N. Schleucher, Tanja Trarbach, José Baselga, Oliver Rosen, Olaf Dirsch and Andreas Kovar and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and British Journal of Cancer.

In The Last Decade

J. Tillner

29 papers receiving 857 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Tillner Germany	14	423	272	268	243	178	29	880
Laila Siam Germany	10	228 0.5×	251 0.9×	102 0.4×	475 2.0×	95 0.5×	12	982
R. Yoshiyuki Osamura Japan	16	196 0.5×	131 0.5×	248 0.9×	201 0.8×	175 1.0×	39	779
Sabina Cuccato Italy	10	444 1.0×	274 1.0×	96 0.4×	324 1.3×	50 0.3×	11	874
Manuela Albertelli Italy	19	478 1.1×	51 0.2×	245 0.9×	147 0.6×	105 0.6×	66	935
Johanna M. U. Silvola Finland	15	92 0.2×	147 0.5×	48 0.2×	312 1.3×	151 0.8×	22	707
Tatsuo Sawada Japan	16	144 0.3×	120 0.4×	57 0.2×	246 1.0×	119 0.7×	56	719
Šime Spaventi Croatia	14	207 0.5×	113 0.4×	122 0.5×	310 1.3×	70 0.4×	23	590
G Strada Italy	14	148 0.3×	277 1.0×	68 0.3×	393 1.6×	117 0.7×	25	761
Marinus A. Noordzij Netherlands	17	296 0.7×	988 3.6×	224 0.8×	625 2.6×	96 0.5×	29	1.4k
Zhihao Zhang China	13	76 0.2×	203 0.7×	62 0.2×	349 1.4×	41 0.2×	36	848

Countries citing papers authored by J. Tillner

Since Specialization

Citations

This map shows the geographic impact of J. Tillner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Tillner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Tillner more than expected).

Fields of papers citing papers by J. Tillner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Tillner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Tillner. The network helps show where J. Tillner may publish in the future.

Co-authorship network of co-authors of J. Tillner

This figure shows the co-authorship network connecting the top 25 collaborators of J. Tillner. A scholar is included among the top collaborators of J. Tillner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Tillner. J. Tillner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Corbin, Karen D., Elvis Á. Carnero, Timothy D. Allerton, et al.. (2023). Glucagon‐like peptide‐1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial. Obesity. 31(2). 350–362. 22 indexed citations

2.

Eriksson, Olof, Irina Velikyan, Torsten Haack, et al.. (2021). Glucagon Like Peptide-1 receptor imaging in individuals with Type 2 Diabetes. Journal of Nuclear Medicine. 63(5). jnumed.121.262506–jnumed.121.262506. 6 indexed citations

3.

Whytock, Katie L., Elvis Á. Carnero, Rick B. Vega, et al.. (2021). Prolonged Glucagon Infusion Does Not Affect Energy Expenditure in Individuals with Overweight/Obesity: A Randomized Trial. Obesity. 29(6). 1003–1013. 25 indexed citations

4.

Eriksson, Olof, Torsten Haack, Youssef Hijazi, et al.. (2020). Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes. Scientific Reports. 10(1). 16758–16758. 34 indexed citations

5.

Eriksson, Olof, Irina Velikyan, Torsten Haack, et al.. (2020). Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes. Journal of Nuclear Medicine. 62(6). 833–838. 8 indexed citations

6.

Wagner, Michael, J. Tillner, Gunnar Antoni, et al.. (2020). Automated GMP-Compliant Production of [68Ga]Ga-DO3A-Tuna-2 for PET Microdosing Studies of the Glucagon Receptor in Humans. Pharmaceuticals. 13(8). 176–176. 4 indexed citations

7.

Tillner, J., Maximilian Posch, Frank Wagner, et al.. (2018). A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials. Diabetes Obesity and Metabolism. 21(1). 120–128. 135 indexed citations

8.

Tillner, J., Anne Lehmann, Zoltán Lukács, et al.. (2015). Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjects. Clinical Pharmacology in Drug Development. 5(1). 57–68. 8 indexed citations

9.

Krösser, Sonja, et al.. (2007). Pharmacokinetics of sarizotan after oral administration of single and repeat doses in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 45(5). 271–280. 6 indexed citations

10.

Kollmannsberger, Christian, Marcus M. Schittenhelm, Friedemann Honecker, et al.. (2006). A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Annals of Oncology. 17(6). 1007–1013. 79 indexed citations

11.

Graeven, Ullrich, B. Kremer, B. Killing, et al.. (2006). Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. British Journal of Cancer. 94(9). 1293–1299. 83 indexed citations

12.

Seiden, Michael V., H. A. Burris, U. Matulonis, et al.. (2005). A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies. Journal of Clinical Oncology. 23(16_suppl). 3151–3151. 8 indexed citations

13.

Trarbach, Tanja, Thomas Beyer, N. Schleucher, et al.. (2004). A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers. Journal of Clinical Oncology. 22(14_suppl). 3018–3018. 11 indexed citations

14.

Tabernero, Josep, Federico Rojo, E. Casado, et al.. (2004). Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). Journal of Clinical Oncology. 22(14_suppl). 2002–2002. 14 indexed citations

15.

Mamo, David C., et al.. (2004). EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. Psychopharmacology. 175(3). 382–388. 14 indexed citations

16.

Trarbach, Tanja, Thomas Beyer, N. Schleucher, et al.. (2004). A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers. Journal of Clinical Oncology. 22(14_suppl). 3018–3018. 4 indexed citations

17.

Graeven, U., Steffen C. Hinz, Wolfram von Bernstorff, et al.. (2004). Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer. Journal of Clinical Oncology. 22(14_suppl). 3061–3061. 4 indexed citations

18.

Graeven, U., Ida Vogel, B. Killing, et al.. (2004). Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer. Journal of Clinical Oncology. 22(14_suppl). 3061–3061. 6 indexed citations

19.

Bokemeyer, Carsten, Christian Kollmannsberger, Marcus M. Schittenhelm, et al.. (2003). 53 A phase I study of epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC). European Journal of Cancer Supplements. 1(5). S20–S21. 7 indexed citations

20.

Danysz, Wojciech, et al.. (2002). Amino-Alkyl-Cyclohexanes as a Novel Class of Uncompetitive NMDA Receptor Antagonists. Current Pharmaceutical Design. 8(10). 835–843. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact